Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects
Glucocorticoids are the most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide. This article highlights the risk of clinically significant and sometimes severe psychological, cognitive, and behavioral disturbances that may be associated with glucocorticoid use, as well as...
Gespeichert in:
Veröffentlicht in: | The American journal of psychiatry 2014-10, Vol.171 (10), p.1045-1051 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1051 |
---|---|
container_issue | 10 |
container_start_page | 1045 |
container_title | The American journal of psychiatry |
container_volume | 171 |
creator | Judd, Lewis L. Schettler, Pamela J. Brown, E. Sherwood Wolkowitz, Owen M. Sternberg, Esther M. Bender, Bruce G. Bulloch, Karen Cidlowski, John A. Ronald de Kloet, E. Fardet, Laurence Joëls, Marian Leung, Donald Y.M. McEwen, Bruce S. Roozendaal, Benno Van Rossum, Elisabeth F.C. Ahn, Junyoung Brown, David W. Plitt, Aaron Singh, Gagandeep |
description | Glucocorticoids are the most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide. This article highlights the risk of clinically significant and sometimes severe psychological, cognitive, and behavioral disturbances that may be associated with glucocorticoid use, as well as ways to prevent and treat these disturbances. An illustrative case vignette is presented describing a patient’s experience of cycles of manic-like behavior and depression while on high-dosage prednisone, with long-term cognitive disorganization, vulnerability to stress, and personality changes. Severe neuropsychiatric consequences (including suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusion, or disorientation) have been reported to occur in 15.7 per 100 person-years at risk for all glucocorticoid courses, and 22.2 per 100 person-years at risk for first courses. The majority of patients experience less severe but distressing and possibly persistent changes in mood, cognition, memory, or behavior during glucocorticoid treatment or withdrawal. Although prediction of such effects is difficult, risks vary with age, gender, dosage, prior psychiatric history, and several biological markers. Key mechanisms thought to underlie these risk factors are briefly described. Recommendations are given for identifying individual risk factors and for monitoring and managing adverse neuropsychiatric effects of glucocorticoids. |
doi_str_mv | 10.1176/appi.ajp.2014.13091264 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1586096755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3466515561</sourcerecordid><originalsourceid>FETCH-LOGICAL-a449t-1f611fb497143645a2572b8b61e3cec36de31beed6882adf91eafef653aaff943</originalsourceid><addsrcrecordid>eNp9kc1O3DAURq2KqkxpXwFF6oYFGXz9l4QdHVFAomoXrdSd5TjX4FEmDnYyEm9fDwOtxIKVZet837V9CDkGugSo1JkZR78063HJKIglcNoAU-IdWYDksqwYqw_IglLKykbyP4fkY0rrvKW8Yh_IIZOsYlyIBbEX3RZjwmIVhoQPMw4WUxFccdXPNtgQJ2-D74rv2HlrJh-G8-JnerT3oQ93-aQ_zcm7wU9-i6eFGbriK96brQ_R9MWlc2in9Im8d6ZP-Pl5PSK_v13-Wl2Xtz-ublYXt6URoplKcArAtaKpQHAlpGGyYm3dKkBu0XLVIYcWsVN1zUznGkDj0CnJjXGuEfyInOx7xxjyS9KkNz5Z7HszYJiTBlkr2qhKyox-eYWuwxyHfDsNKo-v66pRmVJ7ysaQUkSnx-g3Jj5qoHqnQe806KxB7zToFw05ePxcP7cb7P7FXv49A3wPPBX8n_127V8EBpZ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1614388796</pqid></control><display><type>article</type><title>Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Judd, Lewis L. ; Schettler, Pamela J. ; Brown, E. Sherwood ; Wolkowitz, Owen M. ; Sternberg, Esther M. ; Bender, Bruce G. ; Bulloch, Karen ; Cidlowski, John A. ; Ronald de Kloet, E. ; Fardet, Laurence ; Joëls, Marian ; Leung, Donald Y.M. ; McEwen, Bruce S. ; Roozendaal, Benno ; Van Rossum, Elisabeth F.C. ; Ahn, Junyoung ; Brown, David W. ; Plitt, Aaron ; Singh, Gagandeep</creator><creatorcontrib>Judd, Lewis L. ; Schettler, Pamela J. ; Brown, E. Sherwood ; Wolkowitz, Owen M. ; Sternberg, Esther M. ; Bender, Bruce G. ; Bulloch, Karen ; Cidlowski, John A. ; Ronald de Kloet, E. ; Fardet, Laurence ; Joëls, Marian ; Leung, Donald Y.M. ; McEwen, Bruce S. ; Roozendaal, Benno ; Van Rossum, Elisabeth F.C. ; Ahn, Junyoung ; Brown, David W. ; Plitt, Aaron ; Singh, Gagandeep</creatorcontrib><description>Glucocorticoids are the most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide. This article highlights the risk of clinically significant and sometimes severe psychological, cognitive, and behavioral disturbances that may be associated with glucocorticoid use, as well as ways to prevent and treat these disturbances. An illustrative case vignette is presented describing a patient’s experience of cycles of manic-like behavior and depression while on high-dosage prednisone, with long-term cognitive disorganization, vulnerability to stress, and personality changes. Severe neuropsychiatric consequences (including suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusion, or disorientation) have been reported to occur in 15.7 per 100 person-years at risk for all glucocorticoid courses, and 22.2 per 100 person-years at risk for first courses. The majority of patients experience less severe but distressing and possibly persistent changes in mood, cognition, memory, or behavior during glucocorticoid treatment or withdrawal. Although prediction of such effects is difficult, risks vary with age, gender, dosage, prior psychiatric history, and several biological markers. Key mechanisms thought to underlie these risk factors are briefly described. Recommendations are given for identifying individual risk factors and for monitoring and managing adverse neuropsychiatric effects of glucocorticoids.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.2014.13091264</identifier><identifier>PMID: 25272344</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>United States: American Psychiatric Association</publisher><subject>Adults ; Affect - drug effects ; Cognition Disorders - chemically induced ; Cognition Disorders - epidemiology ; Female ; Glucocorticoids - adverse effects ; Hormones ; Humans ; Incidence ; Memory - drug effects ; Mental Disorders - chemically induced ; Mental Disorders - epidemiology ; Middle Aged ; Neuropsychology ; Patients ; Practice Guidelines as Topic ; Psychology - statistics & numerical data ; Risk Factors ; United Kingdom - epidemiology</subject><ispartof>The American journal of psychiatry, 2014-10, Vol.171 (10), p.1045-1051</ispartof><rights>Copyright © 2014 by the American Psychiatric Association 2014</rights><rights>Copyright American Psychiatric Publishing, Inc. Oct 1, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a449t-1f611fb497143645a2572b8b61e3cec36de31beed6882adf91eafef653aaff943</citedby><cites>FETCH-LOGICAL-a449t-1f611fb497143645a2572b8b61e3cec36de31beed6882adf91eafef653aaff943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.2014.13091264$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.2014.13091264$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2842,21605,21606,21607,27901,27902,77537,77542</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25272344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Judd, Lewis L.</creatorcontrib><creatorcontrib>Schettler, Pamela J.</creatorcontrib><creatorcontrib>Brown, E. Sherwood</creatorcontrib><creatorcontrib>Wolkowitz, Owen M.</creatorcontrib><creatorcontrib>Sternberg, Esther M.</creatorcontrib><creatorcontrib>Bender, Bruce G.</creatorcontrib><creatorcontrib>Bulloch, Karen</creatorcontrib><creatorcontrib>Cidlowski, John A.</creatorcontrib><creatorcontrib>Ronald de Kloet, E.</creatorcontrib><creatorcontrib>Fardet, Laurence</creatorcontrib><creatorcontrib>Joëls, Marian</creatorcontrib><creatorcontrib>Leung, Donald Y.M.</creatorcontrib><creatorcontrib>McEwen, Bruce S.</creatorcontrib><creatorcontrib>Roozendaal, Benno</creatorcontrib><creatorcontrib>Van Rossum, Elisabeth F.C.</creatorcontrib><creatorcontrib>Ahn, Junyoung</creatorcontrib><creatorcontrib>Brown, David W.</creatorcontrib><creatorcontrib>Plitt, Aaron</creatorcontrib><creatorcontrib>Singh, Gagandeep</creatorcontrib><title>Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>Glucocorticoids are the most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide. This article highlights the risk of clinically significant and sometimes severe psychological, cognitive, and behavioral disturbances that may be associated with glucocorticoid use, as well as ways to prevent and treat these disturbances. An illustrative case vignette is presented describing a patient’s experience of cycles of manic-like behavior and depression while on high-dosage prednisone, with long-term cognitive disorganization, vulnerability to stress, and personality changes. Severe neuropsychiatric consequences (including suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusion, or disorientation) have been reported to occur in 15.7 per 100 person-years at risk for all glucocorticoid courses, and 22.2 per 100 person-years at risk for first courses. The majority of patients experience less severe but distressing and possibly persistent changes in mood, cognition, memory, or behavior during glucocorticoid treatment or withdrawal. Although prediction of such effects is difficult, risks vary with age, gender, dosage, prior psychiatric history, and several biological markers. Key mechanisms thought to underlie these risk factors are briefly described. Recommendations are given for identifying individual risk factors and for monitoring and managing adverse neuropsychiatric effects of glucocorticoids.</description><subject>Adults</subject><subject>Affect - drug effects</subject><subject>Cognition Disorders - chemically induced</subject><subject>Cognition Disorders - epidemiology</subject><subject>Female</subject><subject>Glucocorticoids - adverse effects</subject><subject>Hormones</subject><subject>Humans</subject><subject>Incidence</subject><subject>Memory - drug effects</subject><subject>Mental Disorders - chemically induced</subject><subject>Mental Disorders - epidemiology</subject><subject>Middle Aged</subject><subject>Neuropsychology</subject><subject>Patients</subject><subject>Practice Guidelines as Topic</subject><subject>Psychology - statistics & numerical data</subject><subject>Risk Factors</subject><subject>United Kingdom - epidemiology</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1O3DAURq2KqkxpXwFF6oYFGXz9l4QdHVFAomoXrdSd5TjX4FEmDnYyEm9fDwOtxIKVZet837V9CDkGugSo1JkZR78063HJKIglcNoAU-IdWYDksqwYqw_IglLKykbyP4fkY0rrvKW8Yh_IIZOsYlyIBbEX3RZjwmIVhoQPMw4WUxFccdXPNtgQJ2-D74rv2HlrJh-G8-JnerT3oQ93-aQ_zcm7wU9-i6eFGbriK96brQ_R9MWlc2in9Im8d6ZP-Pl5PSK_v13-Wl2Xtz-ublYXt6URoplKcArAtaKpQHAlpGGyYm3dKkBu0XLVIYcWsVN1zUznGkDj0CnJjXGuEfyInOx7xxjyS9KkNz5Z7HszYJiTBlkr2qhKyox-eYWuwxyHfDsNKo-v66pRmVJ7ysaQUkSnx-g3Jj5qoHqnQe806KxB7zToFw05ePxcP7cb7P7FXv49A3wPPBX8n_127V8EBpZ8</recordid><startdate>201410</startdate><enddate>201410</enddate><creator>Judd, Lewis L.</creator><creator>Schettler, Pamela J.</creator><creator>Brown, E. Sherwood</creator><creator>Wolkowitz, Owen M.</creator><creator>Sternberg, Esther M.</creator><creator>Bender, Bruce G.</creator><creator>Bulloch, Karen</creator><creator>Cidlowski, John A.</creator><creator>Ronald de Kloet, E.</creator><creator>Fardet, Laurence</creator><creator>Joëls, Marian</creator><creator>Leung, Donald Y.M.</creator><creator>McEwen, Bruce S.</creator><creator>Roozendaal, Benno</creator><creator>Van Rossum, Elisabeth F.C.</creator><creator>Ahn, Junyoung</creator><creator>Brown, David W.</creator><creator>Plitt, Aaron</creator><creator>Singh, Gagandeep</creator><general>American Psychiatric Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201410</creationdate><title>Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects</title><author>Judd, Lewis L. ; Schettler, Pamela J. ; Brown, E. Sherwood ; Wolkowitz, Owen M. ; Sternberg, Esther M. ; Bender, Bruce G. ; Bulloch, Karen ; Cidlowski, John A. ; Ronald de Kloet, E. ; Fardet, Laurence ; Joëls, Marian ; Leung, Donald Y.M. ; McEwen, Bruce S. ; Roozendaal, Benno ; Van Rossum, Elisabeth F.C. ; Ahn, Junyoung ; Brown, David W. ; Plitt, Aaron ; Singh, Gagandeep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a449t-1f611fb497143645a2572b8b61e3cec36de31beed6882adf91eafef653aaff943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adults</topic><topic>Affect - drug effects</topic><topic>Cognition Disorders - chemically induced</topic><topic>Cognition Disorders - epidemiology</topic><topic>Female</topic><topic>Glucocorticoids - adverse effects</topic><topic>Hormones</topic><topic>Humans</topic><topic>Incidence</topic><topic>Memory - drug effects</topic><topic>Mental Disorders - chemically induced</topic><topic>Mental Disorders - epidemiology</topic><topic>Middle Aged</topic><topic>Neuropsychology</topic><topic>Patients</topic><topic>Practice Guidelines as Topic</topic><topic>Psychology - statistics & numerical data</topic><topic>Risk Factors</topic><topic>United Kingdom - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Judd, Lewis L.</creatorcontrib><creatorcontrib>Schettler, Pamela J.</creatorcontrib><creatorcontrib>Brown, E. Sherwood</creatorcontrib><creatorcontrib>Wolkowitz, Owen M.</creatorcontrib><creatorcontrib>Sternberg, Esther M.</creatorcontrib><creatorcontrib>Bender, Bruce G.</creatorcontrib><creatorcontrib>Bulloch, Karen</creatorcontrib><creatorcontrib>Cidlowski, John A.</creatorcontrib><creatorcontrib>Ronald de Kloet, E.</creatorcontrib><creatorcontrib>Fardet, Laurence</creatorcontrib><creatorcontrib>Joëls, Marian</creatorcontrib><creatorcontrib>Leung, Donald Y.M.</creatorcontrib><creatorcontrib>McEwen, Bruce S.</creatorcontrib><creatorcontrib>Roozendaal, Benno</creatorcontrib><creatorcontrib>Van Rossum, Elisabeth F.C.</creatorcontrib><creatorcontrib>Ahn, Junyoung</creatorcontrib><creatorcontrib>Brown, David W.</creatorcontrib><creatorcontrib>Plitt, Aaron</creatorcontrib><creatorcontrib>Singh, Gagandeep</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Judd, Lewis L.</au><au>Schettler, Pamela J.</au><au>Brown, E. Sherwood</au><au>Wolkowitz, Owen M.</au><au>Sternberg, Esther M.</au><au>Bender, Bruce G.</au><au>Bulloch, Karen</au><au>Cidlowski, John A.</au><au>Ronald de Kloet, E.</au><au>Fardet, Laurence</au><au>Joëls, Marian</au><au>Leung, Donald Y.M.</au><au>McEwen, Bruce S.</au><au>Roozendaal, Benno</au><au>Van Rossum, Elisabeth F.C.</au><au>Ahn, Junyoung</au><au>Brown, David W.</au><au>Plitt, Aaron</au><au>Singh, Gagandeep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2014-10</date><risdate>2014</risdate><volume>171</volume><issue>10</issue><spage>1045</spage><epage>1051</epage><pages>1045-1051</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>Glucocorticoids are the most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide. This article highlights the risk of clinically significant and sometimes severe psychological, cognitive, and behavioral disturbances that may be associated with glucocorticoid use, as well as ways to prevent and treat these disturbances. An illustrative case vignette is presented describing a patient’s experience of cycles of manic-like behavior and depression while on high-dosage prednisone, with long-term cognitive disorganization, vulnerability to stress, and personality changes. Severe neuropsychiatric consequences (including suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusion, or disorientation) have been reported to occur in 15.7 per 100 person-years at risk for all glucocorticoid courses, and 22.2 per 100 person-years at risk for first courses. The majority of patients experience less severe but distressing and possibly persistent changes in mood, cognition, memory, or behavior during glucocorticoid treatment or withdrawal. Although prediction of such effects is difficult, risks vary with age, gender, dosage, prior psychiatric history, and several biological markers. Key mechanisms thought to underlie these risk factors are briefly described. Recommendations are given for identifying individual risk factors and for monitoring and managing adverse neuropsychiatric effects of glucocorticoids.</abstract><cop>United States</cop><pub>American Psychiatric Association</pub><pmid>25272344</pmid><doi>10.1176/appi.ajp.2014.13091264</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 2014-10, Vol.171 (10), p.1045-1051 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_1586096755 |
source | MEDLINE; American Psychiatric Publishing Journals (1997-Present); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adults Affect - drug effects Cognition Disorders - chemically induced Cognition Disorders - epidemiology Female Glucocorticoids - adverse effects Hormones Humans Incidence Memory - drug effects Mental Disorders - chemically induced Mental Disorders - epidemiology Middle Aged Neuropsychology Patients Practice Guidelines as Topic Psychology - statistics & numerical data Risk Factors United Kingdom - epidemiology |
title | Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20Consequences%20of%20Glucocorticoid%20Medication:%20Psychological,%20Cognitive,%20and%20Behavioral%20Effects&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Judd,%20Lewis%20L.&rft.date=2014-10&rft.volume=171&rft.issue=10&rft.spage=1045&rft.epage=1051&rft.pages=1045-1051&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.2014.13091264&rft_dat=%3Cproquest_cross%3E3466515561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1614388796&rft_id=info:pmid/25272344&rfr_iscdi=true |